ClinicalTrials.gg
TerminatedNCT00229788Updated Jun 13, 2007

Impact of Race and Re-Transplantation

An observational study in Orthotopic Heart Transplantation, sponsored by Children's Healthcare of Atlanta. Terminated at 1 site in United States. Open to participants aged 1 Day to 18 Years. Per ClinicalTrials.gov, last updated 2007-06-13.

Sponsored by Children's Healthcare of Atlanta · Observational

Study type
Observational
Model
Defined population
Time perspective
Retrospective
Ages
1 Day to 18 Years
Sex
All
01

Study summary

For children who develop graft failure following cardiac transplantation, retransplantation is often considered. While some centers have reported equivalent results for retransplantation as compared to primary transplantation, this strategy remains controversial. We seek to examine outcomes following re-transplantation in children and identify risk factors for mortality. In addition, adult African-Americans have been reported to have lower survival following heart and other solid-organ transplantation. The relationship of recipient race to survival following pediatric heart transplantation has not previously been reported.

Read the detailed description

Objective 1: For children who develop graft failure following cardiac transplantation, retransplantation is often considered. While some centers have reported equivalent results for retransplantation as compared to primary transplantation, this strategy remains controversial. We seek to examine outcomes following re-transplantation in children and identify risk factors for mortality.

Objective 2: Adult African-Americans have been reported to have lower survival following heart and other solid-organ transplantation. The relationship of recipient race to survival following pediatric heart transplantation has not previously been reported.

Methods: We would like to review the United Network for Organ Sharing database. We plan on reviewing database records of heart transplantation subjects \<18 years of age from 1987 to 2004. Indications for retransplantation and patient race characteristics will be collected and evaluated. Analysis will be performed using proportional hazards regression controlling for other potential risk factors. The contribution economic disparity, insurance status and HLA mismatching to disparities in outcome will also be explored.

02

Conditions studied

  • Orthotopic Heart Transplantation

Keywords

  • orthotopic heart transplantation
03

In context

Lead sponsor

Children's Healthcare of Atlanta is the lead sponsor of 97 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Day to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • orthotopic heart transplantation
  • \< 18 years of age

Exclusion criteria

Exclusion Criteria:

-

05

Study design

Observational model
Defined population
Time perspective
Retrospective
06

Study locations

1 site
  • Children's Healthcare of Atlanta
    Atlanta, Georgia 30322, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 13, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00229788
Lead sponsor
Children's Healthcare of Atlanta
First posted
Sep 30, 2005
Start date
Mar 2005
Last update
Jun 13, 2007

Study contacts

William Mahle, MD
principal investigator · Emory University and Children's Healthcare of Atlanta
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion